Ponezumab is a humanized monoclonal antibody designed for the treatment of Alzheimer’s disease.Ponezumab was developed by Pfizer Inc.In November 2011 Pfizer halted the development of ponezumab after finishing a phase 2 trial. Detailed reports have to be released.
This page contains content from the copyrighted Wikipedia article "Ponezumab"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.